​

AbCellera Biologics (ABCL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ABCL Stock Forecast

AbCellera Biologics (ABCL) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $15.40, with a high of $30.00 and a low of $7.00. This represents a 35.44% increase from the last price of $11.37.

- $6 $12 $18 $24 $30 High: $30 Avg: $15.4 Low: $7 Last Closed Price: $11.37

ABCL Stock Rating

AbCellera Biologics stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (91.67%), 1 Hold (8.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 12 0 1 11 Strong Sell Sell Hold Buy Strong Buy

ABCL Price Target Upside V Benchmarks

TypeNameUpside
StockAbCellera Biologics35.44%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts246
Avg Price Target$15.50$17.50$14.17
Last Closing Price$11.37$11.37$11.37
Upside/Downside36.32%53.91%24.63%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26281--11
Sep, 2618---9
Aug, 2618---9
Jul, 26171--9
Jun, 26171--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 11, 2026UBS$18.00$12.5543.43%58.31%
Sep 24, 2026Goldman Sachs$13.00$12.315.61%14.34%
Aug 11, 2026Truist Financial$30.00$10.08197.62%163.85%
Aug 06, 2026Stifel Nicolaus$9.00$6.1247.06%-20.84%
May 12, 2026Stifel Nicolaus$8.00$5.2552.38%-29.64%
May 05, 2026Cantor Fitzgerald$7.00$4.5952.51%-38.43%
Nov 05, 2024Gary NachmanBMO Capital$5.00$2.7482.48%-56.02%
Aug 23, 2024Scott SchoenhausKeyBanc$5.00$2.6092.31%-56.02%
May 08, 2024Scott SchoenhausKeyBanc$7.00$3.8482.29%-38.43%
Jan 06, 2023Leerink Partners$18.00$9.6386.92%58.31%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 11, 2026UBSBuyinitialise
Jul 07, 2026BenchmarkHoldBuyupgrade
May 05, 2026Cantor FitzgeraldOverweightinitialise
Aug 08, 2025BMO CapitalOutperformOutperformhold
Nov 05, 2024BMO CapitalOutperformOutperformhold
Aug 23, 2024KeyBancOverweightOverweighthold
Aug 20, 2024BenchmarkBuyHolddowngrade
Jun 28, 2024Cowen & Co.BuyBuyhold
May 08, 2024KeyBancOverweightOverweighthold
Aug 31, 2023BenchmarkBuyBuyhold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.56$0.56$-0.51$-0.55$-0.49---
Avg Forecast$0.52$0.67$-0.46$-0.59$-0.57$-0.49$-0.22$-0.08
High Forecast$0.90$1.44$-0.41$-0.54$-0.42$-0.29$-0.21$-0.03
Low Forecast$0.29$0.31$-0.52$-0.61$-0.71$-0.69$-0.23$-0.20
Surprise %7.69%-16.42%10.87%-6.78%-14.04%---

Revenue Forecast

$0 $200M $400M $600M $800M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$375.20M$485.42M$38.02M$28.83M$75.13M---
Avg Forecast$354.36M$519.16M$38.13M$31.58M$43.34M$64.22M$106.56M$145.17M
High Forecast$547.69M$982.07M$44.20M$36.12M$89.68M$137.45M$228.07M$310.70M
Low Forecast$233.75M$305.35M$35.50M$28.75M$22.51M$30.84M$51.17M$69.71M
Surprise %5.88%-6.50%-0.27%-8.70%73.34%---

Net Income Forecast

$-250M $-110M $30M $170M $310M $450M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$153.46M$158.52M$-146.40M$-162.86M$-146.41M---
Avg Forecast$151.47M$193.13M$-146.40M$-165.46M$-162.95M$-141.84M$-63.62M$-23.13M
High Forecast$258.90M$416.99M$-119.11M$-155.39M$-120.19M$-85.11M$-61.32M$-7.50M
Low Forecast$84.45M$89.73M$-149.57M$-175.54M$-205.70M$-198.58M$-65.92M$-57.43M
Surprise %1.31%-17.92%--1.58%-10.15%---

ABCL Forecast FAQ

Is AbCellera Biologics stock a buy?

AbCellera Biologics stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that AbCellera Biologics is a favorable investment for most analysts.

What is AbCellera Biologics's price target?

AbCellera Biologics's price target, set by 12 Wall Street analysts, averages $15.4 over the next 12 months. The price target range spans from $7 at the low end to $30 at the high end, suggesting a potential 35.44% change from the previous closing price of $11.37.

How does AbCellera Biologics stock forecast compare to its benchmarks?

AbCellera Biologics's stock forecast shows a 35.44% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for AbCellera Biologics over the past three months?

  • October 2026: 18.18% Strong Buy, 72.73% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is AbCellera Biologics’s EPS forecast?

AbCellera Biologics's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.49, marking a 0% decrease from the reported $-0.49 in 2025. Estimates for the following years are $-0.22 in 2027, and $-0.08 in 2028.

What is AbCellera Biologics’s revenue forecast?

AbCellera Biologics's average annual revenue forecast for its fiscal year ending in December 2026 is $64.22M, reflecting a -14.52% decrease from the reported $75.13M in 2025. The forecast for 2027 is $106.56M, and $145.17M for 2028.

What is AbCellera Biologics’s net income forecast?

AbCellera Biologics's net income forecast for the fiscal year ending in December 2026 stands at $-142M, representing a -3.12% decrease from the reported $-146M in 2025. Projections indicate $-63.617M in 2027, and $-23.133M in 2028.